Subramanian Sanjay 4
4 · Inozyme Pharma, Inc. · Filed Mar 22, 2022
Insider Transaction Report
Form 4
Subramanian Sanjay
SVP, CFO & Head of BD
Transactions
- Award
Stock option (right to buy)
2022-03-21+180,000→ 180,000 totalExercise: $3.96Exp: 2032-03-20→ Common Stock (180,000 underlying)
Footnotes (1)
- [F1]The option was granted on March 21, 2022 and is scheduled to vest 25% on the first anniversary of the grant date. The remainder of the shares underlying the option are scheduled to vest in equal monthly installments over the following three years until the fourth anniversary of the grant date.